LMU

LMU Names Estela Zarate as Dean of LMU School of Education

Retrieved on: 
星期二, 四月 23, 2024
Doctor of Philosophy, UCLA, School, University, Educational leadership, Catholic Church, University of California, Irvine, Teaching, Partnership, Research, UC, STEM, School of education, Master, Faculty, California State University, UTEP, Multimedia, Student, Loyola Marymount University, CSUF, Moses Austin, Rice University, Strategic planning, LMU, Management

LOS ANGELES, April 23, 2024 /PRNewswire/ -- Estela Zarate, a nationally recognized higher education leader whose commitment to student success, anti-racism, equity, and civic engagement embodies the Loyola Marymount University mission, will be the next dean of LMU's School of Education, the university announced today.

Key Points: 
  • LOS ANGELES, April 23, 2024 /PRNewswire/ -- Estela Zarate, a nationally recognized higher education leader whose commitment to student success, anti-racism, equity, and civic engagement embodies the Loyola Marymount University mission, will be the next dean of LMU's School of Education, the university announced today.
  • Zarate has served in leadership roles that include vice provost of Academic Affairs and coordinator of the Master of Science in education administration and Preliminary Administrative Services Credential programs in CSUF's Department of Educational Leadership.
  • "I am looking forward to collaborating with faculty who are committed to a vision of equitable and anti-racist education and mental health systems," Zarate said.
  • Zarate earned a Bachelor of Arts in mathematical economic analysis from Rice University and a Ph.D. in education from UCLA.

John Legend, Janelle Monáe to Speak at LMU Commencements

Retrieved on: 
星期二, 四月 23, 2024
Moonlight, Get Lifted, Grammy Awards, Academy Awards, Tony Awards, McDonald's, Hidden Figures, Legend, Suicide, LEGEND, NBC, Kate Hudson, Television, Memory, The Voice, Music, Human voice, Multimedia, Dirty Computer, Sunken Gardens, LMU

Over his illustrious career, Legend has released seven celebrated solo albums, from "Get Lifted" to "LEGEND," showcasing his evolution as an artist committed to pushing the boundaries of music.

Key Points: 
  • Over his illustrious career, Legend has released seven celebrated solo albums, from "Get Lifted" to "LEGEND," showcasing his evolution as an artist committed to pushing the boundaries of music.
  • Monáe is a multi-hyphenate, ten-time Grammy-nominated artist, New York Times best-selling author, actor, and fashion icon.
  • Following her critically acclaimed 2018 album "Dirty Computer," Monáe recently released "The Age of Pleasure" in June 2023.
  • More than 2,400 undergraduate and graduate students will participate in LMU's commencement exercises, which will be held at Sunken Garden on the LMU Westchester campus and streamed live.

Loretta Martinez Named Inaugural Senior Vice President and General Counsel of LMU

Retrieved on: 
星期一, 二月 26, 2024
Catholic Church, City, CUNY, Multimedia, Education, Loyola Marymount University, Harvard Law School, University, Private sector, Colorado College, Yale University, Knowledge, LMU, City University, Management

LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Loretta P. Martinez, J.D., an accomplished attorney with more than 25 years of experience, primarily as general counsel in public and private higher education institutions, will be the inaugural senior vice president and general counsel of Loyola Marymount University.

Key Points: 
  • LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Loretta P. Martinez, J.D., an accomplished attorney with more than 25 years of experience, primarily as general counsel in public and private higher education institutions, will be the inaugural senior vice president and general counsel of Loyola Marymount University.
  • "I am excited to bring my background as a higher education general counsel to a university with LMU's national reputation and impact," Martinez said.
  • At Colorado College, Martinez served as general counsel and board secretary for more than eight years.
  • Martinez earned her Juris Doctorate at Harvard Law School and her Bachelor of Arts in political science from Yale University.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
星期一, 二月 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
星期一, 二月 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

EQS-News: Ludwig-Maximilian-University of Munich uses artificial intelligence from NorCom

Retrieved on: 
星期四, 二月 8, 2024
Intelligence, LMU, Research, Teaching, Artificial intelligence, News, CPO, Student, Medical device

NorCom is pleased to announce its collaboration with the Ludwig-Maximilian-University of Munich (LMU) on an innovative project.

Key Points: 
  • NorCom is pleased to announce its collaboration with the Ludwig-Maximilian-University of Munich (LMU) on an innovative project.
  • In a pioneering step, the DaSense AI platform will be integrated into a basic seminar on the topic of “Artificial Intelligence and Law – Opportunities, Challenges and Limits”, which will be led by Dr. Ann-Kristin Mayrhofer.
  • LMU, known for its progressive approach to teaching and research, offers students the unique opportunity to expand legal skills by using artificial intelligence (AI).
  • NorCom looks forward to seeing the results of this seminar and continuing to develop innovative solutions for educational institutions and businesses worldwide.

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)

Retrieved on: 
星期五, 十二月 22, 2023
Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Disease, Quality of life, LMU, Neurology, Hospital, Șaeș, PB, Medication, AMX0035, European, Tauopathy, Caregiver burden, MDS, Clinical trial, Movement disorder, Amylyx Pharmaceuticals, PSP, Safety, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of progressive supranuclear palsy (PSP).

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of progressive supranuclear palsy (PSP).
  • Safety and tolerability will be evaluated by assessing the frequency of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs).
  • “AMX0035 has a strong scientific rationale in PSP, targeting key upstream pathways in disease pathophysiology including the unfolded protein response and mitochondrial dysfunction.
  • “Given PSP is a relentlessly progressive disease, it is imperative that we respond to the unmet needs of the community with a sense of urgency.

LMU Names Brietta Clark, J.D., as Next Fritz B. Burns Dean of LMU Loyola Law School

Retrieved on: 
星期二, 十二月 19, 2023
LMU, Faculty, American Journal, Bioethics, Student, Research, Health law, Trustee, Social justice, Education, LLS, University, Loyola Marymount University, Publication, Public health, Nursing

LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- In a historic move, Loyola Marymount University (LMU) announced that it has appointed Brietta Clark, J.D., as the new Fritz B. Burns Dean of LMU Loyola Law School. This makes Clark, who is the 19th dean of the law school, the first woman to hold the position and also the first Black dean in the law school's history. Dean Clark has served as interim dean since July 16, 2023.

Key Points: 
  • LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- In a historic move, Loyola Marymount University (LMU) announced that it has appointed Brietta Clark, J.D., as the new Fritz B. Burns Dean of LMU Loyola Law School.
  • This makes Clark, who is the 19th dean of the law school, the first woman to hold the position and also the first Black dean in the law school's history.
  • Since joining the law school faculty in 2001, Clark has been instrumental in developing and implementing the law school's strategic vision.
  • During her tenure, she has served in numerous leadership roles in addition to interim dean, including associate dean for faculty from 2015-20.

LMU Names Richard Fox as Dean of the Bellarmine College of Liberal Arts

Retrieved on: 
星期三, 十月 25, 2023
Faculty, Political science, Education, UC, Court, Government, System, Complex normal distribution, Fox, Research, Loyola Marymount University, LMU, Multimedia, Bellarmine University, Curriculum, Student, Teaching, Faculty of Political Science and International Relations, Matej Bel University, Union College, Incoming, Liberal arts education, Faculty of Law, Political Science and Criminology of the University of Liège, Woman, Master of Arts, University of California, Santa Barbara, Book, Management, Nursing, Politics

Fox, a professor of political science and director of the LMU International Relations program, joined the university in 2007.

Key Points: 
  • Fox, a professor of political science and director of the LMU International Relations program, joined the university in 2007.
  • During his tenure, he also has served as associate chair and chair of Political Science and International Relations, and as associate dean of BCLA.
  • "While Professor Fox will be missed in the classroom, I am overjoyed for Dean Fox as he transitions into this BCLA leadership role."
  • Fox earned a Bachelor of Arts in Government from Claremont McKenna College and earned both his Master of Arts and Ph.D. in Political Science from UC Santa Barbara.

Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium

Retrieved on: 
星期四, 十月 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PSP, ORION, Progressive supranuclear palsy, Movement disorder, Pan Pacific Hotels and Resorts, Medication, MDS, Neurology, AMX0035, Disease, Aggregation, Ludwig Maximilian University of Munich, Unfolded protein response, HIV disease progression rates, LMU, Quality of life, Department of Neurology, Xuanwu hospital, Caregiver burden, Safety, Hospital, Pharmaceutical industry, Medical imaging, Amylyx Pharmaceuticals, MD

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced an upcoming presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in progressive supranuclear palsy (PSP).

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced an upcoming presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in progressive supranuclear palsy (PSP).
  • Neuro2023: The PSP and CBD International Research Symposium will take place on October 19-20, 2023, at the Pan Pacific Hotel in London, UK.
  • The ORION Phase 3 trial was designed and planned in collaboration with key global academic leaders, people living with PSP, and industry advocacy groups.
  • Additional details regarding trial enrollment and eligibility criteria will be shared upon initiation of the trial, which is anticipated to start by the end of 2023.